These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24861358)

  • 41. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.
    van den Reek JM; van Lümig PP; Driessen RJ; van de Kerkhof PC; Seyger MM; Kievit W; de Jong EM
    Br J Dermatol; 2014 Feb; 170(2):415-24. PubMed ID: 24117023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
    Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of etanercept in psoriatic patients previously treated with infliximab.
    Pitarch G; Sánchez-Carazo JL; Mahiques L; Oliver V
    Dermatology; 2008; 216(4):312-6. PubMed ID: 18230978
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The influence of treatments in daily clinical practice on the Children's Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry.
    Oostveen AM; de Jager ME; van de Kerkhof PC; Donders AR; de Jong EM; Seyger MM
    Br J Dermatol; 2012 Jul; 167(1):145-9. PubMed ID: 22616669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Psoriasis.
    Lebwohl M
    Lancet; 2003 Apr; 361(9364):1197-204. PubMed ID: 12686053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
    Ferrándiz C; García A; Blasco AJ; Lázaro P
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
    Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
    Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The return of investment of translational research in inflammatory dermatoses.
    van de Kerkhof PC
    J Dermatolog Treat; 2008; 19(6):317. PubMed ID: 18982511
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical and economic impact of etanercept in real-life: a prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER).
    Larsen CG; Andersen PH; Lorentzen H; Zachariae C; Huldt-Nystrøm T; Dotterud LK; Lindkvist RM; Qvitzau S
    Eur J Dermatol; 2013; 23(6):774-81. PubMed ID: 24334009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
    Prinz JC; Fitzgerald O; Boggs RI; Foehl J; Robertson D; Pedersen R; Molta CT; Freundlich B
    J Eur Acad Dermatol Venereol; 2011 May; 25(5):559-64. PubMed ID: 20840349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system.
    Terranova L; Mattozzi C; Richetta AG; Mantuano M; Cardosi L; Teruzzi C
    G Ital Dermatol Venereol; 2014 Feb; 149(1):131-43. PubMed ID: 24566574
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
    Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
    J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab.
    Al-Mutairi N; Nour T; Al-Rqobah D
    Expert Opin Biol Ther; 2013 May; 13(5):625-9. PubMed ID: 23527597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
    Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
    Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Biological therapeutic agents and patient autonomy in dermatologic therapy. The Danish Society of Dermatology].
    Bygum A; Jemec GB
    Ugeskr Laeger; 2004 Mar; 166(12):1105. PubMed ID: 15067764
    [No Abstract]   [Full Text] [Related]  

  • 59. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.
    Gisondi P; Conti A; Galdo G; Piaserico S; De Simone C; Girolomoni G
    Br J Dermatol; 2013 May; 168(5):1124-7. PubMed ID: 23320916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.
    Kerdel F; Zaiac M
    Dermatol Ther; 2015; 28(6):390-403. PubMed ID: 26258910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.